Os melhores médicos para o tratamento de Leucemia linfoblástica aguda no exterior — Página 3

O Dr. Ofer Spielberg é um onco-hematologista especializado, focado em cânceres do sangue, como a leucemia.

• Atende no Centro Médico Assuta
• Especialista em onco-hematologia, a área dedicada aos cânceres do sangue
• Fornece tratamento direcionado para leucemia linfoblástica aguda

O Dr. Avichai Shimoni é o diretor de transplante de medula óssea no Sheba Medical Center. Ele trata cânceres sanguíneos complexos. Concluiu uma bolsa de estudos especializada no MD Anderson Cancer Center. O Dr. Shimoni utiliza transplantes alogênicos e autólogos para pacientes de alto risco. Ele é professor e presidente de Hematologia na Universidade de Tel Aviv.

• Nomeado entre os melhores médicos de Israel pela Forbes para 2025 e 2026.
• Autor de mais de 250 artigos científicos sobre terapias celulares e transplantes.
• Fornece terapia de células T com CAR para leucemia, linfoma e mieloma múltiplo.
• Trabalha no Sheba Medical Center, um dos 10 melhores hospitais do mundo segundo a Newsweek.

O Dr. Abraham Avigdor é o Diretor do Instituto de Hematologia do Centro Médico Sheba. Ele é uma autoridade global em linfoma, terapia CAR-T e cânceres complexos do sangue. O Dr. Avigdor fundou o Grupo de Trabalho de Linfoma de Israel. Ele ajuda a liderar uma clínica classificada em 7º lugar mundial pela Newsweek em 2026.

• Autor de mais de 130 publicações científicas sobre hemato-oncologia e terapia celular.
• Pioneiro na integração da terapia de células CAR-T para linfoma e mieloma.
• Lidera programas de transplante de medula óssea alogênico e autólogo.
• Serviu como Presidente do Grupo de Estudo de Linfoma de Israel.

A Dra. Hila Magen é uma hemato-oncologista israelense líder no Sheba Medical Center. Ela chefia a Unidade de Mieloma Múltiplo e Amiloidose. A Dra. Magen é especializada no tratamento de distúrbios complexos de células plasmáticas e mieloma de alto risco. Ela é pesquisadora principal de programas inovadores de terapia CAR-T no local de atendimento. Seu trabalho traz imunoterapias avançadas para o cuidado clínico de rotina.

• Autora de mais de 100 publicações científicas e estudos fundamentais sobre mieloma.
• Completou fellowships no MD Anderson e na Universidade de Ciências Médicas do Arkansas.
• Realiza terapia com células CAR-T e transplantes de medula óssea.
• Trabalha no Sheba Medical Center, classificado em 7º lugar mundial em 2026 pela Newsweek.

Reconhecido pela Forbes como um dos melhores médicos em 2018, o Dr. Stepensky realizou mais de 3.500 transplantes de medula óssea no Hadassah Medical Center.

• 28 anos de experiência de especialização em transplantes de medula óssea pediátricos
• Focado em doenças raras de câncer no sangue em crianças
• Conhecido entre os pacientes como 'aquele que transplanta vida'
• Lidera uma unidade dedicada à hematologia pediátrica

A Dra. Iris Kventsel é hemato-oncologista pediátrica e especialista em transplante de medula óssea no Sheba Medical Center. Ela trata sarcomas infantis, como o sarcoma de Ewing e o osteossarcoma, no Hospital Infantil Edmond e Lily Safra. A Dra. Kventsel integra terapias direcionadas com tratamentos celulares para cânceres infantis complexos. Ela faz parte do corpo docente da Faculdade de Medicina da Universidade de Tel Aviv.

• Especializada em transplante de medula óssea e terapia com células CAR-T para pacientes pediátricos.
• Pesquisa a predisposição genética ao câncer, incluindo a síndrome de Li-Fraumeni e genes de suscetibilidade.
• Publica em periódicos importantes sobre biologia de células-tronco e oncologia cirúrgica (HIPEC).
• Trabalha no Sheba Medical Center, classificado entre os 10 melhores hospitais do mundo.

O Dr. Elad Jacoby é um pioneiro da terapia com células CAR-T pediátricas em Israel. Ele chefia o Centro de Terapia Celular Pediátrica no Sheba Medical Center. O Dr. Jacoby é especializado no tratamento de leucemias e linfomas pediátricos recorrentes e de alto risco. Ele completou bolsas de estudo na Johns Hopkins e no Instituto Nacional do Câncer dos EUA.

• Diretor médico do Centro de Bioterapia Avançada no Sheba Medical Center.
• Autor de mais de 240 publicações científicas em hemato-oncologia pediátrica.
• Certificado em Pediatria e em Hematologia e Oncologia Pediátrica.
• Lidera a integração da terapia com células CAR-T com o transplante de medula óssea.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Líder mundialmente reconhecido em leucemia linfocítica crônica (LLC) e linfomas – o Dr. Bosch é pioneiro em novos tratamentos e pesquisa molecular no Hospital Quiron de Barcelona.

• Lidera mais de 80 ensaios clínicos, da fase 1 à fase 3
• Publicou mais de 100 estudos em revistas de alto impacto como NEJM e Nature Medicine
• Chefia o grupo espanhol de pesquisa e ensaios clínicos em LLC
• Pós-doutorado no Instituto de Genética do Câncer da Universidade de Columbia

Chefe de Hematologia no Hadassah Medical Center – A Professora Ben-yehuda foi pioneira em terapia genética e transplantes de medula óssea para leucemia linfoblástica aguda.

• Formada no Memorial Sloan-Kettering Cancer Center em Nova York
• Primeira mulher a ser reitora da Faculdade de Medicina Hadassah
• Especializada em diagnóstico molecular e imunologia
• Recebedora do prêmio "Healing with the Heart" pelo atendimento excepcional ao paciente

A professora Zila Zuckerman especializa-se em hematologia e transplantologia no Rambam Medical Center.

• Especialista no tratamento da leucemia linfoblástica aguda
• Especializada em transplantologia para doenças do sangue
• Professora com vasta experiência académica e clínica

A Prof. Elke Jaeger é uma das melhores oncologistas da Alemanha segundo o ranking Focus – ela lidera a Oncologia e Hematologia na Clínica Nordwest.

• Especializada no tratamento de sarcomas
• 41 anos de experiência de experiência em oncologia
• Chefe do departamento de Oncologia e Hematologia

Chefe de Hematologia na Clínica Nordwest com 36 anos de experiência de experiência – O Dr. Weidmann especializa-se em tratamentos de doenças do sangue.

• Foca-se em casos de linfoma não-Hodgkin
• Professor com vasta experiência académica e clínica
• Lidera um setor de hematologia dedicado

Professor Associado em Hematologia com mais de 50 publicações – O Dr. Eren é especializado em doenças do sangue no Hospital Universitário Biruni.

• Concluiu a subespecialização em Hematologia no Hospital de Formação e Investigação de Istambul
• Membro da Sociedade Europeia de Hematologia e da Associação Turca de Hematologia
• Vencedor do prémio de Jovem Investigador no Congresso Nacional de Hematologia
• Fluente em inglês para consultas internacionais de pacientes

O Dr. Apak especializa-se em hematologia-oncologia pediátrica com mais de _doctor_6792_ anos de experiência, focando-se na leucemia linfoblástica aguda no Hospital Universitário Biruni.

• Especialista em transplante de medula óssea e terapia com células CAR-T
• Autor de 75 publicações internacionais em oncologia pediátrica
• Chefe da Divisão de Hematologia-Oncologia Pediátrica na Universidade de Istambul-Cerrahpaşa
• Membro da Sociedade Pediátrica Turca e da Associação Turca de Medicina do Adolescente

O professor Fabio Ciceri lidera ensaios pioneiros de terapia celular e genética para leucemia linfoblástica aguda no Hospital San Raffaele.

• Chefe da Unidade de Hematologia e Transplante de Medula Óssea
• Investigador principal em ensaios clínicos para cânceres hematológicos
• Autor de mais de 180 artigos científicos
• Membro do Grupo Europeu de Transplante de Sangue e Medula Óssea

Chefe de um dos maiores departamentos de transplante de medula óssea da Itália – o Dr. Peccatori supervisiona mais de 90 transplantes alogênicos anualmente no San Raffaele.

• 29 anos de experiência de experiência em hematologia e transplante de medula óssea
• Autor de mais de 70 estudos sobre leucemia, mieloma e transplante
• Especializado em transplantes alogênicos para leucemias agudas
• Membro de sociedades europeias e italianas de transplante
• Realizou mais de 900 tratamentos, incluindo casos complexos

Especialista em leucemia aguda e transplante de células-tronco – o Professor Omay traz 36 anos de experiência de experiência em hematologia das principais instituições da Turquia.

• Chefe do Departamento de Hematologia do Hospital Emsey
• Formado em hematologia molecular na Mie Medical School, no Japão
• Publicou mais de 65 artigos científicos sobre tratamentos hematológicos
• Realiza transplantes de células-tronco autólogos e alogênicos